ArticleNature communications2024
HKDC1 promotes tumor immune evasion in hepatocellular carcinoma by coupling cytoskeleton to STAT1 activation and PD-L1 expression.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
8.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 36 citations in OpenAlex.
- HKDC1 as a Prognostic and Tumor Microenvironment‑Associated Biomarker in Colorectal Cancer: An Integrated Multi‑omics and Spatial Transcriptomic Study.Digestive diseases and sciences · 2026Article
- Review
- Identification of STAT1 as a biomarker for lymph node metastasis in esophageal squamous cell carcinoma.Journal of molecular histology · 2026Article
- PiggyBac-Engineered Membrane-Bound IL7 TILs Combined with Anti-PD-1 Antibody Demonstrates Efficacy in Recurrent Ovarian Cancer: A First-in-Human Phase I Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- The evolving landscape of the Warburg effect in gastric cancer: From molecular mechanisms to targeted therapy.Clinical and translational medicine · 2026Review
- PIK3CB depletion restores immunosurveillance and enhances radioactive iodine response in hepatocellular carcinoma.Cell biology and toxicology · 2026Article
- HKDC1-mediated polyamine rewiring drives lenvatinib resistance and immune escape in hepatocellular carcinoma.Clinical and molecular hepatology · 2026Article
- Soft fibrin matrix instructs macrophage M2 polarization via FABP4-mediated enhancement of fatty acid β-oxidation to alleviate MASH.Cellular and molecular life sciences : CMLS · 2026Article
- Targeting the ZDHHC9-mediated STAT1 palmitoylation-phosphorylation conversion inhibits gastric cancer progression.Journal of gastroenterology · 2026Article
- Article
- Targeting SPAK suppresses progression and averts an immune exhaustive microenvironment in hepatocellular carcinoma.Nature communications · 2026Article
- Circadian Clock Genes in Colorectal Cancer: From Molecular Mechanisms to Chronotherapeutic Applications.Biomedicines · 2026Review
- Epigenetic reprogramming of hexokinase domain containing 1 (HKDC1) promotes proliferation in colorectal cancer.American journal of cancer research · 2026Article
- The role of PD‑1/PD‑L1 axis in liver diseases.Clinical and experimental medicine · 2025Review
- Enhancing anti-tumor immunity by targeting BATF and the STAT1/PD-L1 pathway in cervical carcinoma.Cellular and molecular life sciences : CMLS · 2025Article
- Menin regulates YBX1 nucleus translocation to boost the HKDC1 transcription and affects pancreatic cancer glycolysis.iScience · 2025Article
- Transforming acidic coiled-coil-containing protein 3-mediated lipid metabolism reprogramming impairs CD8Signal transduction and targeted therapy · 2025Article
- Glucose metabolism and its direct action in cancer and immune regulation: opportunities and challenges for metabolic targeting.Journal of biomedical science · 2025Review
- LPS mediates cuproptosis and inflammation in THP-1 macrophages through HKDC1.Acta biochimica et biophysica Sinica · 2025Article
- Deletion of epithelial HKDC1 decelerates cellular proliferation and impairs mitochondrial function of tumorous epithelial cells thereby protecting from intestinal carcinogenesis.Cancer communications (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 1 country.
Yi Zhang *School of Medicine, South China University of Technology, Guangzhou, China.
Mingjie Wang *School of Medicine, South China University of Technology, Guangzhou, China.
Ling Ye *The Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, China.
Shengqi ShenMedical Research Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Yuxi ZhangSchool of Medicine, South China University of Technology, Guangzhou, China.
Xiaoyu QianSchool of Medicine, South China University of Technology, Guangzhou, China.
Tong ZhangMedical Research Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
Mengqiu YuanThe Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, China.
Zijian YeSchool of Medicine, South China University of Technology, Guangzhou, China.
Jin CaiSchool of Medicine, South China University of Technology, Guangzhou, China.
Xiang MengSchool of Medicine, South China University of Technology, Guangzhou, China.
Shiqiao QiuSchool of Medicine, South China University of Technology, Guangzhou, China.
Shengzhi LiuSchool of Medicine, South China University of Technology, Guangzhou, China.
Rui LiuThe Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, China.
Weidong JiaAnhui Key Laboratory of Hepatopancreatobiliary Surgery, Department of General Surgery, Anhui Provincial Hospital, the First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, China.
Xianzhu YangSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, China. yangxz@scut.edu.cn.ORCID 0000-0002-1006-0950
Huafeng ZhangThe Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, China. hzhang22@ustc.edu.cn.ORCID 0000-0001-9923-7531
Xiuying ZhongMedical Research Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China. zxywawj@ustc.edu.cn.ORCID 0000-0002-1616-1330
Ping GaoSchool of Medicine, South China University of Technology, Guangzhou, China. pgao2@ustc.edu.cn.ORCID 0000-0002-6930-7989
South China University of Technology · CNGuangdong Academy of Medical Sciences · CNUniversity of Science and Technology of China · CN
Funding
National Natural Science Foundation of China (National Science Foundation of China) 81930083National Natural Science Foundation of China (National Science Foundation of China) 82072656National Natural Science Foundation of China (National Science Foundation of China) 82130087National Natural Science Foundation of China (National Science Foundation of China) 82192893National Natural Science Foundation of China (National Science Foundation of China) 82322050National Natural Science Foundation of China (National Science Foundation of China) 82341013National Natural Science Foundation of China (National Science Foundation of China) 92357301National Natural Science Foundation of China (National Science Foundation of China) U22A20156
Abstract
Immune checkpoint blockade (ICB) has shown considerable promise for treating various malignancies, but only a subset of cancer patients benefit from immune checkpoint inhibitor therapy because of immune evasion and immune-related adverse events (irAEs). The mechanisms underlying how tumor cells regulate immune cell response remain largely unknown. Here we show that hexokinase domain component 1 (HKDC1) promotes tumor immune evasion in a CD8
Indexed as
Carcinoma, HepatocellularLiver NeoplasmsAnimalsB7-H1 AntigenCell Line, TumorCytoskeletonHexokinaseHumansImmune EvasionMaleMiceSTAT1 Transcription FactorTumor EscapeB7-H1 AntigenCD274 protein, humanCd274 protein, mouseHexokinaseHKDC1 protein, humanHkdc1 protein, mouseSTAT1 protein, humanStat1 protein, mouseSTAT1 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.